Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Neemol** is an orally administered Ayurvedic proprietary multi-herb syrup marketed by United Pharmaceuticals. The manufacturer describes Neemol Syrup as a preparation containing neem leaves, bark, and fruit with other herbs, promoted for skin-related concerns and immune support. Public product information identifies a botanical mixture that includes *Azadirachta indica*, *Hemidesmus indicus*, *Terminalia chebula*, *Terminalia bellirica*, *Emblica officinalis*, *Tinospora cordifolia*, *Acacia catechu*, *Bauhinia variegata*, and *Psoralea corylifolia*. No defined molecular target, pharmacologically validated mechanism, clinical-development program, or regulatory approval for a specific disease was identified in the reviewed sources. ([unitedneemol.com](https://unitedneemol.com/index.html))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Neemol.